Summary of the period FINANCIAL OVERVIEW · Net revenue increased by 54 percent to TSEK 5,622 (3,654) · The operating profit and loss for the period was TSEK -6,768 (-6,032) · Profit and loss after tax for the period was TSEK -7,845 (-6,705) · Earnings per share for the period was SEK -0.28 (-0.40) · Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST
Nanologica AB (publ) has changed the previously disclosed publication date of April 23, 2021 for the company’s annual report 2020 to May 5, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual Report 2020 May 5, 2021 Interim report January-June 2021
Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27. Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of Technology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021. Before that, Thomas was the Vice President
Thomas Eldered, som nyligen lämnade sin post som vd för Recipharm och som är Nanologicas största aktieägare, föreslås av valberedningen i Nanologica att väljas in som ledamot i styrelsen vid årsstämman den 27 maj. Thomas Eldered är civilingenjör i industriell ekonomi från Linköpings tekniska högskola och ärmedgrundare av Recipharm AB, där han också var verksam som vd mellan 2008–2021. Före det varThomas Vice President för Recip AB 1995–2007. Valberedningen föreslår i övrigt omval av Gisela
Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27. Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute ofTechnology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021.Before that, Thomas was the Vice President of Recip
Nanologica AB (publ) has changed the previously disclosed publication date of May 7, 2021 for the Company’s interim report for the first quarter 2021 to April 23, 2021. In addition, the date for the interim report for the second quarter 2021 has been changed from August 27, 2021 to July 9, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual
